This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft-versus-host disease.

Join Kenneth Anderson, MD and Paul Richardson, MD as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.

Join Kenneth Anderson, MD and Paul Richardson, MD as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

The NCCN 2014 Nursing Program Webinar Series: Advancing Oncology Nursing™ will provide the oncology nurse with comprehensive and clinically relevant information regarding the management of patients with cancer.

Join Carol Ann Huff, MD, and Ivan Borrello, MD, as they present their multidisciplinary expertise on a range of cases pertaining to multiple myeloma.